Medical providers specializing in metabolic health Clinics focused on metabolic optimization, hormone health, and weight management often provide guidance on peptide therapy options
Authorization was required for 5% or fewer of beneficiaries until 2024, then by 2025, it was required for nearly 100% (Figure 1)
Consider seeking advice if you experience irregular or absent periods, unexplained weight gain that does not respond to lifestyle changes, symptoms of excess androgens such as hirsutism or persistent acne, or if you are struggling with fertility concerns
Working with Your Healthcare Provider Never stop taking GLP-1 medications on your own always consult your healthcare provider
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2 Trial (NEJM 2023)PubMed 2023 TRIUMPH-1: Phase 3 study of LY3437943 in adults with obesityClinicalTrials.gov 2024 Retatrutide is an investigational drug currently in Phase 3 clinical trials
FAQ Is compounded semaglutide the same as Ozempic